Introduction: This study examined whether 355 obese patients with type 2 diabetes (T2D) of varying duration and severity experienced equivalent weight loss and T2D remission following a newer sleeve gastrectomy (SG) procedure - SG with transit bipartition (SG-TB).
Methods: Primary outcomes were changes in body mass index (BMI), total weight loss (TWL), excess BMI loss (EBMIL), A1C, and diabetes medication use through 24 months.
Results: Between December 2015 and December 2019, 399 patients who underwent SG-TB reached the 2-year time point. Follow-up was possible in 355 patients (89.0%): 206 females (58.0%), mean age 51.5 years (24.0-73.0), BMI 34.0 kg/m2 (28.0-50.5), and T2D duration 12.0 years (4.0-37.0). At 2 years, total sample respective mean TWL and EBMIL were 20.2 ± 6.1% (95% CI: 19.5, 20.8) and 87.7 ± 35.2% (84.1, 91.4) corresponding to mean BMI change of 7.0 ± 2.7 kg/m2 (6.7, 7.3) (p < 0.001). T2D duration and severity subgroups experienced comparable BMI and A1C change from baseline (p < 0.001); 281 (79.2%) maintained complete remission. ANOVA showed significant mean increases in vitamin D, calcium, and albumin: overall complication rate, 10.2%; no mortality.
Discussion/conclusion: In 355 patients with obesity who underwent SG-TB, excellent weight loss, T2D, and nutritional outcomes were seen at 2-year follow-up regardless of preoperative T2D duration and severity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669945 | PMC |
http://dx.doi.org/10.1159/000526718 | DOI Listing |
Curr Nutr Rep
January 2025
Research and Development cell, Department of Intellectual property Rights, Lovely Professional University, Jalandhar- Delhi Grand Trunk Rd., Phagwara, Punjab, 144411, India.
Purpose Of Review: This review explores the mechanistic pathways and clinical implications of phytochemicals in obesity management, addressing the global health crisis of obesity and the pressing need for effective, natural strategies to combat this epidemic.
Recent Findings: Phytochemicals demonstrate significant potential in obesity control through various molecular mechanisms. These include the modulation of adipogenesis, regulation of lipid metabolism, enhancement of energy expenditure, and suppression of appetite.
Metab Brain Dis
January 2025
Department of Biochemistry, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaounde, Cameroon.
Alzheimer's disease (AD) is associated with cognitive impairments which are linked to a deficit in cholinergic function. The objective of this study was to evaluate the ability of TeMac™ to prevent memory impairment in scopolamine-rats model of Alzheimer's disease and by in silico approaches to identify molecules in TeMac™ inhibiting acetylcholinesterase. The cholinergic cognitive dysfunction was induced by intraperitoneal injection of scopolamine (1 mg/kg daily) in male Wistar rats for seven consecutive days.
View Article and Find Full Text PDFBackground: Abdominoplasty may be considered a procedure performed after a patient has already lost weight, but many surgeons have clinically observed that patients continue to lose weight in the postoperative period. This study sought to quantify continued weight loss after abdominoplasty procedures.
Methods: A retrospective chart review was conducted on all abdominoplasty cases performed by the senior author between 2018 and 2022.
Food Funct
January 2025
Institute for Innovative Development of Food Industry, Shenzhen University, Shenzhen 518060, China.
: carbohydrate-restricted diets (CRDs) have gained attention to address metabolic dysregulation commonly observed in dyslipidemia, a condition posing significant risks to cardiovascular health. However, the effectiveness of CRDs in improving cardiovascular health remains contentious. This meta-analysis comprehensively evaluated the long-term effects of CRDs on glucolipid metabolism and weight loss in individuals with dyslipidemia.
View Article and Find Full Text PDFCureus
January 2025
Faculty of Medicine, University of Hama, Hama, SYR.
Paradoxical reactions (PRs) to biologic medications, such as psoriasis, arthritis, and inflammatory bowel disease (IBD), have been increasingly recognized. The aim of reporting this case is to establish an association between golimumab and exacerbation or new (de novo) IBD in patients with axial spondyloarthritis (SpA). Our case involves a young patient with juvenile-onset ankylosing spondylitis (AS) who developed de novo IBD following golimumab therapy for active spinal disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!